Français

Українська

English

العربية

Deutsch

Français

Italiano

Español

Ελληνικά

Türkçe

Srpski

中文
+38 067 935 25 44
00380689869898 (汉语)
00380930552240 (لغه العربية)
00380930552240 (باللغة العربية)
infocenter@emcell.com
+38 067 935 25 44
infocenter@emcell.com
Demande dinfos
Top traitements Traitement de l'autisme Traitement anti-âge Traitement des maladies du coeur Traitement de diabete Traitement de sclérose en plaques Traitement des dystrophies musculaires Anémie Amyotrophie spinale Arthrite rhumatoïde Cancer Colite ulcéreuse et maladie de Crohn Dysfonction érectile Hypertension artérielle Le traitement de Parkinson Maladie d’Alzheimer SLA/Maladie du neurone moteur Infertilité masculine
Top traitements Traitement de l\'autisme Traitement anti-âge Traitement des maladies du coeur Traitement de diabete Traitement de sclérose en plaques Traitement des dystrophies musculaires
Voir tout
Anémie Amyotrophie spinale Arthrite rhumatoïde Cancer Colite ulcéreuse et maladie de Crohn Dysfonction érectile Hypertension artérielle Le traitement de Parkinson Maladie d’Alzheimer SLA/Maladie du neurone moteur Infertilité masculine
Cacher

Menu du site

Our licences

→
→
→
Demande dinfos

Tables

Table 1. The peripheral blood counts in patients with oncological and hematological disturbances after fetal stem cell transplantation
Table 2. Contents of leukocytes in peripheral blood after chemotherapy in hematological patients after fetal stem cells transplantation and in a control group
Table 3. Recovery of total leukocytes and neutrophyls in hematological patients with severe postchemotherapy neutropenia after fetal stem cells transplantation
Table 4. Peripheral blood indices in patients with cervical cancer after cell therapy (n=23)
Table 5. Immune indices in patients with cervical cancer after fetal stem cells transplantation
Table 6. Psychophysiological changes in cancer patients after the fetal stem cell transplantation

Table 1. The peripheral blood counts in patients with oncological and hematological disturbances after fetal stem cell transplantation (n=26)

Term of observation Erythrocytes
1012/l
M ± m 		Hemoglobin
g/l
M ± m 		Thrombocytes
109/l
M ± m 		Leukocytes
109/l
M ± m
Before treatment
 2.65 ± 0.15 78.19 ± 4.25 79.40 ± 16.42 1.37 ± 0.16
After FSCT (days)
3 2.72 ± 0.13 79.39 ± 3.91 133.20 ± 38.39 1.90 ± 0.31
5 2.75 ± 0.13 82.42 ± 3.51 191.92 ± 55.92 3.12 ± 1.05
7 2.87 ± 0.13 84.77 ± 3.52 153.34 ± 37.35 4.46 ± 1.78
11 3.12 ± 0.15 91.27 ± 3.54 164.23 ± 29.54 4.21 ± 0.69
13 3.40 ± 0.16 96.19 ± 3.50 212.65 ± 37.95 4.68 ± 0.89
30 3.51 ± 0.16 103.27 ± 3.67 163.73 ± 20.00 5.20 ± 1.01

Table 2. Contents of leukocytes in peripheral blood after chemotherapy in hematological patients after fetal stem cells transplantation (n=26) and in a control group (n=30)

Days after Transplantation

After Fetal Stem Cells Transplantation (n=26)

Control group (n=30)

 

M m % M m %
0 1.37 0.16 100 1.20 0.07 100
3 1.90 0.31 138 1.17 0.09 97.5
5 3.12 1.05 228 — — —
7 4.46 1.78 325 1.18 0.11 97.7
11 4.21 0.69 307 1.51 0.15 126
13 4.68 0.89 341 2.10 0.20 175
30 5.20 1.01 379 4.10 0.48 341

Table 3. Recovery of total leukocytes and neutrophyls in hematological patients with severe postchemotherapy neutropenia after fetal stem cells transplantation (n=16)

Days after transplantation Total leukocytes Neutrophils

 

M m % M m %
0 0.98 0.17 100 0.18 0.07 100
3 1.24 0.14 126 0.40 0.12 222
5 3.02 1.56 308 1.76 1.24 977
7 4.79 2.89 488 2.18 1,627  
11 3.59 0.91 366 1.79 0.76 994
13 3.78 1.17 385 2.06 0.95 1,144
30 4.83 1.50 492 1.95 0.54 1,083

Table 4. Peripheral blood indices in patients with cervical cancer after cell therapy (n=23)

Blood indices St.in Before
stem cell therapy 		Days after cell therapy
3 7 11 15 30

Erythrocytes, 1012/l

M
m
p 		3.60
0.11 		3.54
0.19 		3.59
0.16 		3.62
0.17 		4.05
0.21 		3.89
0.19

Hemoglobin, G/l

M
m
p 		111.4
6.0 		106.3
5.25 		109.9
5.08 		111.5
4.79 		115.8
4.53 		120.7
4.33

Leukocytes, 109/l

M
m
p 		2.66
0.29 		3.14

0.53 		3.83
0.49
<0.05 		3.53
0.52 		3.36
0.28
<0.05 		3.55
0.24
<0.01

Neutroph. stab, %

M
m
p 		6.29
1.38 		5.14
1.03 		4.93
0.55 		5.50
1.29 		5.79
1.35 		5.38
1.02

Neutroph. stab, G/l

M
m
p 		180.9
34.1 		154.6
41.6 		190.7
30.3 		269.0
115.3 		198.4
46.3 		199.8
44.8

Neutroph. segmented, %

M
m
p 		54.3
2.56 		58.6
2.73 		58.7
2.38 		64.1
2.57
<0.01 		63.1
1.90
<0.005 		64.7
2.54
<0.005

Neutrophils segm., 109/l

M
m
p 		1.48
0.20 		1.84
0.31 		2.29
0.33
<0.05 		2.24
2.98
<0.05 		2.04
0.16
<0.05 		2.18
0.08
<0.05

Lymphocytes, %

M
m
p 		20.6
2.06 		20.9
2.31 		23.1
1.80 		17.2
1.62 		18.6
1.95 		15.7
1.93

Lymphocytes, 109/l

M
m
p 		0.55
0.07 		0.75
0.22 		0.89
0.18 		0.59
0.09 		0.63
0.10 		0.48
0.06

Monocytes, %

M
m
p 		8.21
0.86 		9.29
1.15 		9.64
1.04 		8.50
1.47 		7.14
1.03 		8.23
1.27

Monocytes, 109/l

M
m
p 		0.21
0.02 		0.27
0.04 		0.34
0.04
0.05 		0.32
0.08 		0.23
0.03 		0.27
0.05

Table 5. Immune indices in patients with cervical cancer after fetal stem cells transplantation

Immunological tests Before
FSCT 		Two weeks
after FSCT 		After
radiotherapy
n=7 n=7 n=7
M m M m M m
Leukocytes, 109/l 2.90 0.14 3.91 0.38 3.54 0.40
Lymphocytes, % 16.00 4.62 16.71 2.13 20.14 3.84
B-lymphocytes, (CD19+), % 13.96 1.64 10.21 1.33 11.00 0.63
B-lymphocytes, per mm3 66.34 23.74 68.02 15.5 70.76 8.75
T-lymphocytes, (CD3+), % 38.42 7.87 39.71 5.13 50.71 3.97
T-lymphocytes, per mm3 168.98 67.03 254.90 58.9 332.62 54.16
T-helpers (CD4+), % 25.46 5.76 27.14 3.62 33.59 2.40
T-helpers, mm3 112.11 47.36 177.90 44.9 220.12 34.76
T-suppressers (CD8+), % 12.31 2.66 15.08 1.56 18.86 2.01
T-suppressers, mm3 59.85 26.95 95.65 17.9 121.17 18.50
NK-cells (CD16+), % 17.30 2.63 21.94 6.04 15.56 1.90
NK-cells (CD16+), per mm3 84.55 32.98 129.87 34.3 95.01 8.79
CD4+/CD8+ 2.03 0.36 1.70 0.11 1.77 0.09

Table 6. Psychophysiological changes in cancer patients after the fetal stem cell transplantation

75 clinical cases were analyzed: with cytostatic disease (50), without signs of cytostatic disease (25). Assessment of disorders of psychic condition, depressive symptoms, emotional changes, spirits, and changes of thinking, memory and intellect were carried out.
  Before
FSCT 		First 6–12 hours 1–3
days 		5–10
days 		3–6
weeks 		3–6
months
State of spirit
Depression +++ – – – – +
Composure, optimism – + + + ++ ++
Desperation +++ – – – + +
Tranquillity, hope – – + + ++ ++
Emotional sphere
Self awareness – + ++ + ++ ++
Activity – ++ + ++ ++ ++
Anxiety ++ + + – – +
Stability of emotional state – + + ++ ++ ++
Mental capacity
Attention (strength and stability of concentration), + ++ +++ + ++ ++
Improvement of thinking process, memory, creativity, decreasing of manifestations of senile dementia + + ++ ++ +++ +++
Improvement of contact with doctors and people around + ++ ++ ++ ++ ++
Improvement of quality of sleeping – + ++ ++ ++ +
Sexual energy – – + ++ + +
Nos contacts

EmCell Centre de Thérapie Cellulaire

e-mail adresse: ​infocenter@emcell.com

notre adresse:

03143, Kyiv, ​40A Metrolohichna street, Ukraine

téléphone:

 +38 044 223 28 95

portable:

 +38 067 935 25 44
WhatsApp Viber wechat
Demande dinfos
© 1999-2020 EmCell.com